BioCentury
ARTICLE | Distillery Therapeutics

Cancer

July 17, 2018 5:38 PM UTC

Patient sample and mouse studies suggest inhibiting NEK2 could help treat Velcade bortezomib-resistant MM. In MM patients, high levels of NEK2 in bone marrow plasma cells were associated with poor overall and event-free survival. In two xenograft mouse models of Velcade-resistant MM, two tool compound NEK2 inhibitors plus Velcade decreased tumor size compared with Velcade alone or vehicle. Next steps could include identifying novel NEK2 inhibitors and testing them in models of Velcade-resistant MM...